Market Access Essentials: Joint Clinical Assessment (EU) JCA

Name: Market Access Essentials: Joint Clinical Assessment (EU) JCA
Rating: 5.0 (5 reviews)

Created byAccess Health Academy

Last updated 11/2025

English

English [Auto],

What you'll learn

Map and architect JCA-ready PICOs and EU comparator strategies that reflect real-world SoC.
Design pivotal evidence “fit for JCA” (H2H, pragmatic, external control) using estimands you can defend.
Execute Bucher/NMA/MAIC/STC with proper assumptions, diagnostics, and pre-planned sensitivity ladders.
Build target-trial RWE with robust confounding control and full provenance for replication.
Operationalize outcomes, surrogates, PROs/HRQoL (MIDs, TTD) and safety (AESIs/EAIRs) for decision-grade interpretation.
Author a reproducible JCA dossier (tables, figures, traceability index, D-series code bundle) that assessors can rerun.
Convert JCA to national P&R: absolute effects, rebuttal kits, pricing/MEAs, tenders—under a war-room, RACI, risk & QA model.

Course content

5 sections • 25 lectures • 7h 1m total length

Why JCA matters in 2025 (scope, waves, transition)21:05
Explore how the 2025 joint clinical assessment (JCA) shifts EU HTA to a single EU level for oncology medicines and atmps, accelerating market access and shaping evidence strategy.
Regulation (EU) 2021/2282 in plain English16:23
Explain how the EU health technology assessment regulation creates a single EU joint clinical assessment with one shared evidence synthesis, while leaving budget impact and pricing decisions to national authorities.
Governance: Coordination Group, subgroups, roles of patients/clinicians15:44
Explain the EU HTA governance framework, including the HTA coordination group and four permanent subgroups, and the meaningful, independent roles of patients and clinicians.
What JCA covers vs. what remains national10:51
Explain how the joint clinical assessment standardizes clinical evidence across the EU, while leaving pricing and reimbursement to national decision making. Highlight the division between EU-level evidence and national policy.
Learning Toolkit: Slides and Video Scripts0:01

Critical path: pre-notification → scoping → assessment → adoption13:55
Navigate the four-stage critical path of the EU Joint Clinical Assessment, pre-notification, scoping, assessment, adoption, and align EMA and HTA timelines to deliver an EU clinical narrative for timely access.
Scoping mechanics: PICO collection, consolidation, negotiation25:17
Learn how scoping converts 27 member state questions into a unified pico framework for the EU joint clinical assessment, creating a binding data request.
Submission logistics: dossier structure, portals, validation & Q&A workflow23:21
Structure the JCA dossier, including the narrative core, to align with annex I requirements. Navigate the submission workflow through the HTA IT platform, with timelines, appendices, and completeness check.
Interaction points and common timing pitfalls20:13
Navigate the joint clinical assessment choreography, from submission to publication on the hta platform, outlining assessor roles, feedback cycles, factual accuracy checks, and publication-ready timelines.
Learning Toolkit: Slides and Video Scripts0:01

Mapping standard of care across Member States26:06
Map the european standard of care across eu states with a defensible heat map, triangulated guidelines, hta, utilization data, and drift monitors to define base comparators or variant picos.
PICO architecture: base vs. variant PICOs, dominance/coverage trade-offs24:54
Design a robust pico architecture for joint clinical assessment across Europe, balancing base and variant picos, the individualized treatment comparator, and dominance versus coverage.
Designing pivotal evidence fit for JCA (head-to-head, pragmatic, external contro23:12
Design pivotal evidence fit for JCA by answering the EU level PICO with estimands tied to patient-relevant outcomes and ensuring reproducibility for assessors, emphasizing head-to-head trials and credible comparators.
Bridging gaps: external comparators and ITC rescue plans20:19
Bridge evidence gaps for JCA using anchored ITCs, NMAs, and population-adjusted ITCs or external controls, guided by a target trial mindset with transparent protocols and reproducible code.
Learning Toolkit: Slides and Video Scripts0:01

Internal/external validity & bias tools21:15
Explore internal and external validity in joint clinical assessment, using bias tools, DAGs, and structured frameworks to ensure credible, transportable EU evidence.
ITCs: Bucher, NMA, MAIC/STC—when/how, assumptions, sensitivity ladders26:23
Explore indirect treatment comparisons in joint clinical assessment, from anchored network meta-analysis to unanchored approaches, with IPD and aggregate data, emphasizing transitivity, exchangeability, overlap, and robust preplanned sensitivity analyses.
RWE that survives scrutiny: target trial emulation, confounding control...19:46
Learn to design real world evidence studies for joint clinical assessment using target trial emulation, new user active comparator design, confounding control, and rigorous provenance.
Tricky stats: crossover, missing data, multiplicity, immature OS...24:35
This lecture tackles tricky statistics in JCA, including crossover, missing data, multiplicity, and immature overall survival, emphasizing pre-specified estimands, robust adjustment methods, RMST, and transparent, reproducible analyses.
Learning Toolkit: Slides and Video Scripts0:01

Patient-relevant outcomes hierarchy; endpoint selection logic18:45
Define patient relevant outcomes and select endpoints in EU joint clinical assessment by following a patient-centered hierarchy from final long-term outcomes to surrogates, ensuring transparency and validity.
Surrogates: validation and triangulation21:45
Assess how to validate surrogate endpoints through four pillars—biological plausibility, patient-level and trial-level surrogacy, and transportability—using biomarkers, intermediate endpoints, and composites to inform JCA decisions.
HRQoL/PROs: instruments, MID, cross-walks, interpretation24:57
Select validated PRO and HRQoL instruments, map to utilities when needed, apply anchor-based or distribution-based MIDs, and employ robust longitudinal analyses to interpret patient perspectives and support EU HTA decisions.
Safety synthesis and benefit–risk framing for JCAs22:58
Assess safety synthesis and benefit–risk framing for joint clinical assessments by integrating rigorous, patient-relevant harms with efficacy, using Meddra, SMQs, and predefined Pico questions.
Learning Toolkit: Slides and Video Scripts0:01

Requirements

No requirements

Description

Disclaimer: This course contains the use of AI

This advanced, practice-first course is a complete playbook for succeeding under the EU Joint Clinical Assessment (JCA) from 2025 onward. You’ll learn how to design, defend, and deploy comparative-effectiveness evidence that survives EU-level scrutiny and can be reused—without re-analysis—by Member States for national pricing and reimbursement. We start by demystifying governance, waves, and transition, then move into the operational core: scoping PICOs and mapping standards of care across Member States; building a comparator strategy (including individualized “doctor’s-choice” bundles); and engineering pivotal evidence fit for JCA—head-to-head trials, pragmatic elements, and disciplined external-control designs.

You’ll master indirect comparisons (Bucher, NMA, MAIC/STC), target-trial RWE with audit-ready provenance, and the “tricky stats” that regularly derail submissions (crossover, missing data, multiplicity, immature OS, and HTE). Outcomes, surrogates, PROs/HRQoL (instruments, MIDs, cross-walks), and safety (MedDRA/CTCAE, AESIs, EAIRs) are taught with a focus on patient relevance and interpretability.

On the authoring side, you’ll build a JCA-aligned dossier with evidence tables, traceability, and a small, high-signal figure set that assessors can rerun from your code bundle. Then you’ll translate the JCA into national action: absolute effects, divergence handling, rebuttal kits, pricing/MEAs, and tenders (MEAT/BPQR). Finally, you’ll operationalize the work: a readiness RACI across global–regional–affiliate, a “war-room” model with SLAs, a risk register, comment tracker, vendor pod strategy, layered QA, and a living playbook for annual refresh.

Designed for Market Access, HEOR, RA, Clinical, Biostats, and Medical Writing leaders, the course ships with templates, checklists, and code-ready figure scripts so you can execute immediately—end to end—from PICO to price.

Who this course is for:

Designed for Market Access, HEOR, RA, Clinical, Biostats, and Medical Writing leaders

Market Access Essentials: Joint Clinical Assessment (EU) JCA

What you'll learn

Explore related topics

Course content

JCA Orientation & Regulatory Framework5 lectures • 1hr 4min

JCA Process & Timelines (End-to-End)5 lectures • 1hr 23min

Evidence & Comparator Strategy for JCA5 lectures • 1hr 35min

Methods: Comparative Effectiveness & RWE in JCA5 lectures • 1hr 32min

Outcomes, Endpoints, PROs & Safety5 lectures • 1hr 28min

Requirements

Description

Who this course is for: